Skip to NavigationSkip to content


Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug

Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders led to the approval of a rival treatment.

In June 2019, Catalyst filed a lawsuit against the FDA over their decision to approve a rival treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) by Jacobus Pharmaceuticals. Partially redacted emails from the FDA show that issues arose over the $375,000 list price for Catalysts Firdapse (amifampridine), which led Sanders to allege the company was price gouging.

How do the Presidential frontrunners plan to combat the opioid crisis?

Published on 12/02/20 at 12:58pm

The widespread addiction to extremely potent, legal painkillers has decimated the lives of millions across the United States. Overdoses from opioids have surpassed car crashes and gun violence as the leading cause of death in Americans under the age of 55. The epidemic has killed nearly 400,000 people since 2000 – more people than HIV at the peak of that disease – while its economic cost has been placed between $50 billion and $1 trillion.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches